Study of efficacy of rituximab drug for topical application in oral mucosa in pemphigus vulgaris patients.

Phase 2

Not yet recruiting

• Conditions: Health Condition 1: null- ORAL PEMPHIGUS VULGARIS

• Registration Number: CTRI/2018/05/014187
• Lead Sponsor: Dr SUJAY KHANDPUR

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients with predominant oral Pemphigus vulgaris (defined as oral involvement with cutaneous involvement less than 1%) or

pure oral mucosal involvement diagnosed on basis of clinical features and ELISA for desmoglein 3 antibody with or without positive tzanck smear and mucosal biopsy

2. Patients in age group of 18-72 years.

3. Patients giving consent for participating in study and obtaining mucosal biopsies.

Exclusion Criteria

1. Patients with pemphigus vulgaris with cutaneous involvement more than 1%.

2. Patients unwilling to give consent for study.

3. Patients with history of significant reaction to intravenous rituximab

4. Patients with severe comorbid illness like patients with malignancy, cardiac failure and uncontrolled diabetes mellitus.

Study & Design

• Study Type: Interventional
• Study Design: Not specified